Distinct Response to CTLA-4 Antibodies by Different Tumors Implicates Different Mechanisms of Action
Davy Xuesong Ouyang, Zhung Wang, Gavin Jiagui Qu, Gang Chen*, Annie Xiaoyu An, Jinping Liu, Leo Liu, Vincent Huang, Jay Liu*, Xin Dong*, Henry Q. Li
*Nanjing Galaxy Biopharmaceutical Co. Ltd.
New immunotherapy assessment platforms are needed to progress immuno-oncology agents such as checkpoint inhibitors including CTLA-4. Tumor homograft models and syngeneics can be used to assess mouse surrogate checkpoint inhibitors, with humanized models then needed to evaluate human-specific agents.
We’ve developed immune checkpoint target humanized mice as a cost-effective alternative to complex, fully humanized models. This includes a CTLA-4 model, with humanized CTLA-4 receptors within a functional mouse immune system.
This poster tests different immuno-oncology platforms such as syngeneics, tumor homografts, and our CTLA-4 humanized model with various anti-CTLA-4 antibodies against both mouse and human targets, to explore different mechanisms of sensitivity/resistance.
Read this Poster to Discover:
- That human and mouse CTLA-4 antibodies have different mechanisms of action
- That T cells from the humanized CTLA-4 models express hCTLA-4, providing an ideal model to test human-specific agents
- How tumor homografts and humanized drug target models are particularly useful for investigating the mechanism of action of immunotherapies